Rituximab therapy for childhood-onset systemic lupus erythematosus

Willems, Marjolaine; Haddad, Élie; Niaudet, Patrick; Koné‐Paut, Isabelle; Bensman, A; Cochat, Pierre; Deschênes, Georges; Fakhouri, Fádi; Leblanc, Thierry; Llanas, Brigitte; Loirat, Chantal; Pillet, P.; Ranchin, Bruno; Salomon, Rémi; Ulinski, Tim; Bader-Meunier, Brigitte

doi:10.1016/j.jpeds.2006.01.041

Cited by 125 publications

(134 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unusually high haematological toxicity has been described in a series of paediatric patients. 11 Infusion reactions are similar to those described in patients with lymphoma.…”

Section: Side Effectssupporting

confidence: 59%

“…The risk of infection may be increased in patients who have continued other immunosuppressives. 11 In RA patients treated with rituximab there is evidence that antibodies to microbial antigens such as tetanus toxoid or pneumococcal capsular polysaccharides remain within the protective range following treatment. 12 There is a case for immunising patients against these and other antigens before treatment if their levels are below the protective range and the clinical situation allows it.…”

Section: Side Effectsmentioning

confidence: 99%

See 1 more Smart Citation

B cell depletion in systemic lupus erythematosus

Leandro¹,

Ehrenstein

2007

Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…Unusually high haematological toxicity has been described in a series of paediatric patients. 11 Infusion reactions are similar to those described in patients with lymphoma.…”

Section: Side Effectssupporting

confidence: 59%

Section: Side Effectsmentioning

confidence: 99%

B cell depletion in systemic lupus erythematosus

Leandro¹,

Ehrenstein

2007

Clinical Medicine

View full text Add to dashboard Cite

show abstract

“…10,11,15 A low infection rate and an absence of significant hypogammaglobulinemia were shown in adults and children over 10 years old receiving rituximab for autoimmune diseases. 11,16,17 Conversely, younger children were kept on prophylactic IVIG replacement therapy, 9 but data on serum immunoglobulin levels were not provided. The only severe infection reported in children was an enteroviral meningoencephalitis which occurred after severe immunosuppression.…”

Section: Resultsmentioning

confidence: 99%

Rituximab therapy for childhood Evans syndrome

Bader-Meunier¹,

Aladjidi²,

Bellmann³

et al. 2007

Haematologica

View full text Add to dashboard Cite

The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m 2 per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively.Key words: Evans syndrome, children, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rituximab.

show abstract

“…Rituximab is also an effective maintenance therapy in indolent lymphomas after response to initial therapy [41]. In addition, rituximab has produced promising results in the treatment of autoimmune diseases, including rheumatoid arthritis and certain lupus variants [42][43][44].…”

Section: Rituximabmentioning

confidence: 99%

A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects

Strome¹,

Sausville²,

Mann

2007

The Oncologist

116

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the relationship between antibody structure and effector function, and identify strategies for modifying antibody structure to enhance these functions.2. Explain how the efficacy of monoclonal antibodies in cancer therapy may occur via antibody-as well as targetrelated mechanisms.3. Discuss how the ability of monoclonal antibodies to activate immune-mediated effector functions differs across antibody isotypes.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTSeveral monoclonal antibodies are now in clinical use for cancer therapy, and many others are currently undergoing clinical evaluation. These agents offer unique specificity against key molecular targets on tumor cells or in the tumor microenvironment. The clinical efficacy of monoclonal antibodies is generally attributed to target-specific mechanisms resulting from neutralizing or inhibiting a growth factor or receptor that drives cell proliferation and tumor growth. Several targets, including CD20, human epidermal growth factor receptor 2, vascular endothelial growth factor, and epidermal growth factor receptor, have been validated in specific malignancies on the basis of monoclonal antibody efficacy. However, monoclonal antibodies also have the potential to activate immune-mediated effector functions, including antibody-dependent cellmediated cytotoxicity and complement-dependent cytotoxicity. These functions result from interactions involving the Fc domain of the antibody, and, consequently, may vary by antibody, isotype, and Fc modification, such as changes in glycosylation. Accordingly, all monoclonal antibodies directed against a given target should not be considered equivalent in their ability to stimulate immunemediated effector functions. The Oncologist

show abstract

Rituximab therapy for childhood-onset systemic lupus erythematosus

Cited by 125 publications

References 38 publications

B cell depletion in systemic lupus erythematosus

B cell depletion in systemic lupus erythematosus

Rituximab therapy for childhood Evans syndrome

A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects

Contact Info

Product

Resources

About